What if one click was enough to lose weight? Ozempic, a drug designed for diabetics, is the new trend for those who want to lose weight quickly and without suffering. The drug promises to solve weight problems forever, and for this reason the drug has become very famous and sought after by stars, actresses, VIPs and those who want to appear slimmer and which has been talked about a lot lately.
INSIGHTS
The investigation
On “Petrolio”, broadcast on Tuesday 12 March at 9.20pm on Rai 3, Duilio Giammaria talked about it with the immunologist Antonella Viola, the psychologist Paolo Crepet, the professor Giuseppe Remuzzi, Director of the Mario Negri Institute and Giulia Paganelli, physiatrist of Gimbe, to think about the correct and incorrect uses of drugs and the obsession with the body that overwhelms so many people.
«Here in Northern Rome everyone uses it». The drug for diabetics that makes you lose weight effortlessly.
The investigation of #Petroliumfrom Denmark, where the success of #Ozempic per capita income is changing, right down to our pharmacies with candid cameras.
📌This evening 9.20pm on #Rai3 pic.twitter.com/p4ad4TEkzx
— Rai3 (@RaiTre) March 12, 2024
«Everyone uses it, you lose weight easily»
Petrolio interviewed a woman who used it. «It’s the trend of the moment, here in Northern Rome everyone uses it, at least 8 out of 10 women, even if they don’t admit it», she says. «Even if you are thin, you tend to lose 4 kilos here easily without suffering.
Just spend a little more money.”
How much does it cost and the dosage
A 3 ml pre-filled pen of Ozempic costs around 180 euros. The starting dose is 0.25 mg semaglutide once a week. After 4 weeks, the dose should be increased to 0.5 mg once a week. After at least 4 weeks on a dose of 0.5 mg once weekly, the dose may be increased to 1 mg once weekly to further improve glycemic control. After at least 4 weeks on a 1 mg once weekly dose, the dose may be increased to 2 mg once weekly to further improve glycemic control.
The risks
The most frequently reported adverse reactions during clinical trials were gastrointestinal disorders, including nausea (very common), diarrhea (very common), and vomiting (common). In general, these reactions were mild or moderate in severity and of short duration.
AIFA: the increase in requests creates a state of shortage
With the increase in demand, the drug has become difficult to find, especially for those who suffer from diabetes and need it. This was also confirmed by AIFA, with a note: «The increase in demand for Ozempic has led to shortages that are expected to continue throughout 2023. Although the supply continues to increase, it is not possible to predict with certainty when it will be sufficient to fully satisfy current demand.”
© ALL RIGHTS RESERVED